Codexis (CDXS) Stock Price
Codexis Price
Codexis (CDXS) Stock | ISIN US1920051067 | WKN A0Q2S4. The current Codexis stock price is 2.5 USD (2026). Revenue is 72.22 M USD. Net income is -36.85 M USD. The P/E ratio is -4.98. Market capitalization is 225.8 M USD. Codexis operates in the Health sector.
Codexis stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Codexis over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Codexis stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Codexis's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Codexis Price |
|---|
Codexis Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Codexis Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2024 | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|
| 59 | 68 | 72 | 96 | 129 | 160 | 213 | 291 |
| -15.71 | 15.25 | 5.88 | 33.33 | 34.38 | 24.03 | 33.13 | 36.62 |
| 72.88 | 63.24 | 59.72 | 44.79 | 33.33 | 26.88 | 20.19 | 14.78 |
| 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 |
| -65 | -60 | -36 | -17 | -5 | -14 | -8 | 20 |
| -14.47 | -7.69 | -40 | -52.78 | -70.59 | 180 | -42.86 | -350 |
| 73.41 | 73.41 | 73.41 | 73.41 | 73.41 | 73.41 | 73.41 | 73.41 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Codexis generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Codexis retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Codexis's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Codexis has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Codexis's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Codexis stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Codexis Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Codexis business model & stock analysis
Codexis SWOT Analysis
Strengths
Codexis Inc has a strong and experienced management team, enabling effective decision-making and business strategy implementation. The company possesses cutting-edge biotechnology expertise, allowing it to develop innovative and high-quality products. Codexis also has a strong intellectual property portfolio, which provides a competitive advantage in the industry.
Weaknesses
One of the weaknesses of Codexis Inc is its high dependence on a limited number of key customers. This reliance creates vulnerability in case of any disruptions or changes in customers' preferences. The company also faces challenges in effectively managing its research and development costs, as developing new products requires substantial investments.
Opportunities
Codexis Inc has significant opportunities for growth in the expanding biotechnology and pharmaceutical markets. The increasing demand for sustainable and environmentally friendly solutions presents a favorable market for Codexis' biocatalysis technology. The company can also explore strategic partnerships and collaborations to expand its market reach and access new customers.
Threats
One of the potential threats for Codexis Inc is intense competition in the biotechnology industry. Rival companies with similar technologies and product offerings may limit the market share of Codexis. The company also faces regulatory risks, as changes in government regulations and policies related to biotechnology can impact its operations. Additionally, macroeconomic factors such as economic downturns can affect customer spending and demand for Codexis' products.
Codexis Segments
Codexis Revenue by Segment (1/5)
3 Years
5 Years
Max
Details
Codexis Revenue by Segment (2/5)
3 Years
5 Years
Max
Details
Codexis Revenue by Segment (3/5)
3 Years
5 Years
Max
Details
Codexis Revenue by Segment (4/5)
3 Years
5 Years
Max
Details
Codexis Revenue by Segment (5/5)
3 Years
5 Years
Max
Details
Codexis Revenue by Region
3 Years
5 Years
10 Years
Max
Details
Codexis Eulerpool Fair Value
Codexis historical P/E ratio, EBIT multiple, and P/S ratio
Codexis annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Codexis shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Codexis Earnings Estimates
Codexis Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/7/2026 | -0.15USD | 14.73 MUSD | 2026 Q1 |
| 4/30/2026 | -0.15USD | 14.73 MUSD | 2026 Q1 |
| 3/11/2026 | -0.04USD | 36.55 MUSD | 2025 Q4 |
| 2/26/2026 | -0.04USD | 36.55 MUSD | 2025 Q4 |
| 2/25/2026 | -0.04USD | 36.55 MUSD | 2025 Q4 |
| 8/13/2025 | -0.19USD | 14.39 MUSD | 2025 Q2 |
| 5/2/2024 | -0.19USD | 11.74 MUSD | 2024 Q1 |
| 2/21/2024 | -0.16USD | 17.33 MUSD | 2023 Q4 |
| 8/2/2023 | -0.29USD | 22.47 MUSD | 2023 Q2 |
| 5/3/2023 | -0.34USD | 20.02 MUSD | 2023 Q1 |
EESG©
Eulerpool ESG Scorecard© for the Codexis stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Codexis shareholder structure
| % | Name |
|---|---|
13.96147% | |
7.97166% | |
6.48036% | |
5.08106% | |
4.81668% | |
4.65118% | |
4.4626% | |
4.4287% | |
2.82419% | |
2.18985% |
Codexis Executives and Management Board
Dr. Stephen Dilly
(65)Chairman of the Board, President, Chief Executive Officer · since 2020
Mr. Kevin Norrett
(52)Chief Operating Officer
Dr. Alison Moore
(58)Executive Vice President, Chief Technical Officer · since 2020
Ms. Georgia Erbez
(58)Chief Financial Officer
Mr. David Smith
(65)Lead Independent Director
Frequently asked questions about Codexis
The business model of Codexis Inc is focused on providing sustainable biocatalysis solutions to industries such as pharmaceuticals, food and beverage, and chemicals. Codexis employs proprietary protein engineering technology to create highly efficient biocatalysts that can replace traditional chemical processes, resulting in cost savings, increased product yields, and reduced environmental impact. By collaborating with its customers, Codexis develops customized enzymes and processes that address specific challenges and improve overall efficiency in various manufacturing processes. Codexis aims to offer value-added solutions to help its customers achieve their sustainability goals while maintaining profitability.
Codexis stock
Codexis Peer Group
Codexis Ticker
Codexis FIGI
All fundamentals and in-depth analysis of Codexis
Our stock analysis for Codexis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Codexis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.